glp-1 autoimmune disease Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases | Cell & Bioscience For most patients with inflammatory

No head-to-head trials comparing agents in these two classes are currently available to guide decision-making

Real-world evidence Real-world data can complement trial evidence by evaluating how GLP-1 RAs influence BP in routine clinical practice

This includes adults with an initial BMI of 30 kg/m 2 and above, or 27 to 29.9 kg/m 2 with at least one weight-associated comorbidity (e.g hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or T2DM)

DOSING To improve glycemic control in adults and pediatric patients aged 10 years and older with T2D, the recommended starting dose is 5 mg orally once daily

What are the potential long-term side effects of combination therapies for managing PCOS-related obesity